Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001140361-25-005051
Filing Date
2025-02-19
Accepted
2025-02-18 20:25:20
Documents
15
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A ef20043829_10qa.htm   iXBRL 10-Q/A 63882
2 EXHIBIT 31.1 ef20043829_ex31-1.htm EX-31.1 5122
3 EXHIBIT 31.2 ef20043829_ex31-2.htm EX-31.2 4969
  Complete submission text file 0001140361-25-005051.txt   232902

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA grce-20241231.xsd EX-101.SCH 4093
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE grce-20241231_lab.xml EX-101.LAB 22758
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grce-20241231_pre.xml EX-101.PRE 16583
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20043829_10qa_htm.xml XML 5539
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-322-1602
Grace Therapeutics, Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 10-Q/A | Act: 34 | File No.: 001-35776 | Film No.: 25636906
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)